1Niewoehner DE. Outpatient management of severe COPD. N Engl J Med ,2010,362:1407-1416.
2Cazzola M,MacNee W,Martinez FJ,et al. On behalf of the American Thoracic Society/European Respiratory Society task force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J ,2008,31:416-468.
3Hurst JR.,Vestbo J,Anzueto A,et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med,2010,363:1128-1138.
4National Institute for Health and Clinical Excellence Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London:National Clinical Guideline Centre,2010.
5Van -Gestel YR,Goei D,Hoeks SE,et al. Predictive value of NT- proBNP in vascular surgery patients with COPD and normal left ventricular systohc function. COPD,2010,7:70-75.
6Inoue Y,Kawayama T,Iwanaga T,et al. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med,2009,48: 503-512.
7Yvette R.. B. M. van Gestel,Don D. Sin,Don Poldermans,et al. Elevated N-Terminal Pro-B-Type Natriuretic Peptide Levels:The Effect of Chronic Obstructive Pulmonary Disease. JACC,2009,53(5):458-463.
8Gemici G,Erdim R.,Celiker A,et al. Btype natriuretic peptide levels in patients with COPD and normal right ventricular function. Adv Ther,2008,25 (7) :674-680.
9Pinsky MR.. Through the past darkly ventilatory management of patients with chronic obstructive pulmonary disease. Crit Care Med,1994,22:1714-1717.
10Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis,management and prevention of chronic pulmonary disease,2011.
